, an activator for H-Ras, R-Ras and Rasassociated protein-1/2, has emerged as an important mediator of signaling downstream from receptor coupled phosphoinositide turnover in B and T cells. Here, we report that RasGRP3 showed a high level of expression in multiple human melanoma cell lines as well as in a subset of human melanoma tissue samples. Suppression of endogenous RasGRP3 expression in these melanoma cell lines reduced Ras-GTP formation as well as c-Met expression and Akt phosphorylation downstream from hepatocyte growth factor (HGF) or epidermal growth factor (EGF) stimulation. RasGRP3 suppression also inhibited cell proliferation and reduced both colony formation in soft agar and xenograft tumor growth in immunodeficient mice, demonstrating the importance of RasGRP3 for the transformed phenotype of the melanoma cells. Reciprocally, overexpression of RasGRP3 in human primary melanocytes altered cellular morphology, markedly enhanced cell proliferation and rendered the cells tumorigenic in a mouse xenograft model. Suppression of RasGRP3 expression in these cells inhibited downstream RasGRP3 responses and suppressed cell growth, confirming the functional role of RasGRP3 in the altered behavior of these cells. The identification of the role of RasGRP3 in melanoma highlights its importance, as a Ras activator, in the phosphoinositide signaling pathway in human melanoma and provides a new potential therapeutic target.
Introduction
There is abundant evidence to suggest that Ras is a critical cell signaling element impacting the development, maintenance, and progression of human melanoma, as it is in many other cancers. N-Ras is mutated in 15-20% of human melanomas (Haluska and Ibrahim, 2006) . The overexpression of mutated constitutively activated N-Ras in melanocytes of INK4a À/À background transgenic mice resulted in abnormal proliferation of the melanocytes and development of metastatic cutaneous melanoma (Ackermann et al., 2005) . Although H-Ras is less frequently mutated in melanoma, the expression of a mutated constitutively activated H-Ras in wild-type melanocytes induced melanocytic hyperplasia and contributed to their susceptibility to develop melanoma in vivo (Broome Powell et al., 1999) . Activation of M-Ras was involved in MGSA/ GRO (melanoma growth stimulatory activity/growth regulated protein)-mediated melanocyte transformation (Wang et al., 2000) . Activated R-Ras promoted integrinmediated melanoma cell migration (Gawecka et al., 2010) . In addition, even when not mutated, wild-type Ras showed constitutive activation in many melanoma cell lines but not in normal melanocytes (Satyamoorthy et al., 2003) .
The importance of the Ras signaling pathway in melanoma is further emphasized by the frequency with which mutations are detected in the effector pathways downstream of Ras signaling. Thus, mutations in B-Raf are found in some 60% of melanomas and mutations in phosphatase and tensin homolog, an inhibitor of Akt activity, are found in 30% (Pollock et al., 2003; Wu et al., 2003; Ikediobi et al., 2006) . Similarly, suppression of the Ras/phosphatidylinositide 3-kinase (PI3K) signaling pathway reduced melanoma cell metastasis (Huang et al., 2008) .
Functionally, the RasGRPs act as immediate upstream activators of Ras isoforms. The RasGRPs are regulated both by diacylglycerol binding to the C1 domains as well as through phosphorylation by protein kinase C, which itself is regulated by diacylglycerol (Aiba et al., 2004; Zheng et al., 2005; Stone, 2006) . They should thus respond to the many receptor tyrosine kinases and G-protein coupled receptors which activate phospholipase C isoforms, among other responses, leading to phospholipase C breakdown of phosphatidylinositol 3,5-bisphosphate and generation of diacylglycerol. Therefore, RasGRPs can physiologically and simultaneously activate multiple downstream wild-type Ras family members and link them to signals from the many upstream growth factors or cytokines which drive diacylglycerol turnover, including the B receptor, T-cell receptor, hepatocyte growth factor and epidermal growth factor (Lorenzo et al., 2000 (Lorenzo et al., , 2001 Oh-hora et al., 2003; Aiba et al., 2004; Brodie et al., 2004; Stope et al., 2004; Zheng et al., 2005; Stone, 2006) .
Emerging evidence indicates that RasGRPs can function as oncogenes in multiple cancers. Overexpression of RasGRPs caused Ras activation coincident with cell transformation and tumorigenesis in both mice and human (Suzuki et al., 2002; Oki-Idouchi and Lorenzo, 2007) . Highly expressed RasGRP3 has been found in human Burkitt's lymphoma, human pre-B-cell leukemia and human natural killer-like T-cell leukemia (Teixeira et al., 2003) . Additionally, re-expression of RasGRP3 enhanced angiogenesis during pregnancy and tumorigenesis (Roberts et al., 2004) . We recently reported that RasGRP3 expression was an important contributor to the cancer phenotype in several human prostate cancer cell lines (Yang et al., 2010) .
These observations have motivated a more extensive examination of RasGRP3 expression and function in solid tumors. Here, we examine the role of RasGRP3 in melanoma.
Results
RasGRP3 is expressed in human melanoma tissues and multiple melanoma cell lines We examined the RasGRP3 mRNA expression level in a human melanoma tissue array by mRNA in situ hybridization. In all, 5 out of 40 melanoma tissue samples (samples A2, A5, A6, B4 and D5 in Figure 1a ) (12.5% of the melanomas) showed RasGRP3 expression ( Figure 1a and Supplementary Figure 1A) . None of the eight normal skin samples showed expression ( Figure 1a , columns labeled F). Using quantitative PCR, we also examined a human melanoma complementary DNA array for RasGRP3 expression. Marked variation (65-fold) in inter-individual RasGRP3 expression was observed in the complementary DNA array (Supplementary Figure 1B ). Although we were unable to (Biomax Inc.) were hybridized with antisense probes 1 and 2 generated against two non-overlapping regions of the RasGRP3 mRNA. Sense fragments were used as negative controls. A positive autoradiographic signal is detected in samples #A2, A5, A6, B4 and D5, by both probes. There is no detectable specific signal in the normal skin samples (F columns). Higher magnification pictures (lower panel left and right) show labeled cells within the tissue samples #B4 and #D5 of the array. Silver grains (black dots) deposited over the cells indicate the localization of radiolabeled molecules hybridized to endogenous mRNA. The tissue is stained with Giemsa solution. Scale bars: 100 mm. Expression and function of RasGRP3 in human melanoma D Yang et al address how these levels of RasGRP3 expression in the melanoma tissues compared with normal melanocytes in skin, we could, however, detect the expression of RasGRP3 in most of the tested melanoma cell lines both by immunoblotting (Figure 1b ) and by reverse transcriptase (RT)-PCR (Supplementary Figure 1C) . In the human primary adult melanocytes, the endogenous RasGRP3 expression was not detectable by immunoblotting. The RasGRP3 was also unable to be detected by RT-PCR in the human primary adult melanocytes (not shown). However, melanin binds and inhibits thermostable DNA polymerase (Eckhart et al., 2000; Sutlovic et al., 2005) and the much higher levels of melanin present in the melanocytes than in the melanoma cells lines caused interference, as evidenced by reduced detection of glyceraldehyde 3-phosphate dehydrogenase as well, necessitating caution in interpretation. For comparison with the melanoma cell lines, we included the Ramos B-lymphoblastoid cell line as a positive control in both assays, because the Ramos cells have been described as expressing the highest endogenous level of RasGRP3 (Teixeira et al., 2003) . RasGRP3 protein was highly expressed in the SK-MEL-5 and UACC-257 cell lines (Figure 1b) . It was expressed at a lower level in the SK-MEL-2, UACC-62, M14, MALME-3M and SK-MEL-28 cell lines (Figure 1b for protein and Supplementary Figure 1C for RNA levels). In the human adult primary melanocytes, RasGRP3 expression was not detectable under these conditions (Figure 1b ). It should be noted that there was not exact correspondence between the levels of RasGRP3 protein detected by immunoblotting (Figure 1b ) and the levels of message as detected by RT-PCR (Supplementary Figure 1C) . Thus, whereas SK-MEL-5 showed the highest expression by both methods, the M14 cell line showed relatively lower expression by immunoblotting than by RT-PCR. As we know, for example, that the RasGRP3 antibody response is greater for phosphorylated RasGRP3 (data not shown) than for unphosphorylated RasGRP3, the relative levels should be viewed as approximate.
Downregulation of RasGRP3 suppressed proliferation of multiple human melanoma cell lines
In five of eight melanoma cell lines, transient inhibition of endogenous RasGRP3 expression (Figure 2a ) was accompanied by substantial inhibition of cell proliferation; less (but still significant) inhibition was observed in the LOX-IMVI, SK-MEL-2 and SK-MEL-28 cell lines (Figure 2a) . Although the basis for the reduced response is not known, the LOX-IMVI cells expressed the lowest level of RasGRP3 expression of the cell lines examined. The SK-MEL-2 cells express a constitutively active N-Ras, meaning that this major Ras family member no longer requires an upstream activator, and the SK-MEL-28 cell line is mutated in the EGF receptor (see Supplementary Table 3 for a listing of mutations in each of the cell lines examined) (Ikediobi et al., 2006) . To achieve long-term suppression of RasGRP3 expression, we established cell lines derived from M14 and SK-MEL-5 cells expressing tet-on inducible RasGRP3 short hairpin RNA (shRNA). The specific shRNAs were selected based on their ability to knockdown the exogenous RasGRP3-V5 in RasGRP3-LNCaP cells (Supplementary Figure 2A) and the endogenous RasGRP3 in M14 cells (Supplementary Figure 2B) .
As a result of promoter leakage with the tet-on system, the level of endogenous RasGRP3 expression in the absence of tetracycline was already somewhat reduced in the M14 derivative sh854 cell line and in both of the SK-MEL-5 derivative cell lines, sh236 and sh854 (Figures 2b and c) . To confirm the specificity of the effects of the RasGRP3 shRNAs, we created a mutated variant of RasGRP3 retaining the amino acid sequence of RasGRP3 but altered in its coding sequence to diminish the homology with shRNA854. Stable cell lines were prepared by introducing this RasGRP3 mutant into the SK-MEL-5 derivative sh854 cell line. Tables 1 and 2 ). Deoxytetracycline induction had no effect on tumor growth in control cells. Similarly, in the shRNA854 derived SK-MEL-5 cells expressing the mutated RasGRP3 deoxytetracycline treatment failed to affect tumor growth ( Figure 3d and Table 2 ). Expression of the RasGRP3 mutant did not significantly affect tumor growth, compared with control cells (P ¼ 0.27), in the absence of the shRNA854 induction ( Figure 3d and Table 2 ).
Endogenous RasGRP3 contributes to Ras and Akt1/2/3 activation as well as c-Met expression in multiple melanoma cell lines RasGRP3 has been reported to activate H-Ras, R-Ras, and Ras-associated protein (Rap)1/2, among Ras family members (Yamashita et al., 2000) . To clarify the role of RasGRP3 in melanoma cell signaling, its effects on activation of Ras and downstream effectors were investigated. Inhibition of RasGRP3 expression was accompanied by a reduced level of Ras-GTP in M14, SK-MEL-5, UACC-62 and UACC-257 cells (Figure 4a ), confirming that RasGRP3 was indeed an important contributor to the state of Ras activation in these cells. These results were also confirmed in M14 and SK-MEL-5 cell lines expressing inducible RasGRP3 shRNAs (Supplementary Figure 5C) .
It has been reported that activation of the EGF receptor and the B-cell receptor trigger protein kinase C or Src-mediated RasGRP3 activation through its phosphorylation followed by activation of the Ras pathway ( Figure 4A) . HGF treatment led to Akt phosphorylation at Ser473 in M14, SK-MEL-5, UACC-257 (Figure 4a ), SK-MEL-2, SK-MEL-28 and MALME-3M cells (Supplementary Figure 4A) . In the UACC-62 cells, HGF was without effect but instead EGF enhanced Akt phosphorylation (Supplementary Figure 4A) . Transient suppression of endogenous RasGRP3 decreased both basal and HGFinduced Akt phosphorylation in the M14, SK-MEL-5 and UACC-257 cells (Figure 4a and Supplementary Figure 5A ), as well as the SK-MEL-28 cells (Supplementary Figure 5B ). In the UACC-62 cells, suppression Figure 4B) . Expression of c-Met, the receptor for HGF, was also affected by the level of RasGRP3. Inhibition of RasGRP3 expression led to reduction of c-Met expression in both M14 and SK-MEL-5 cell lines (Figure 4c ).
Transformation of human adult melanocytes by overexpressing RasGRP3
To further explore the biological role of RasGRP3 in human melanoma, we overexpressed RasGRP3-V5 in human adult primary melanocytes (Pu et al., 2005) . Relative to the control melanocytes, the RasGRP3 overexpressing melanocytes showed a cuboidal shape with shorter, less numerous processes resembling SK-MEL-5 cells (Figure 5a ). The RasGRP3-melanocytes lost or showed greatly diminished expression of the melanocyte After 3 weeks antibiotic selection, the stable RasGRP3-melanocytes showed a markedly enhanced growth rate comparing with control melanocytes, without melanocyte growth medium. The doubling time of the cells is around 12 h (Figure 5c ). Furthermore, following subcutaneous injection of these cells (after 3 weeks of antibiotic selection), they formed tumors in immunodeficient mice, whereas no detectable growth was observed for control melanocytes (Figure 5d ). As a further control in this system, reduction in the level of exogenous RasGRP3 expression markedly retarded the RasGRP3-melanocyte's proliferation (Figure 5e ), accompanied by a reduced level of basal Akt phosphorylation (Figure 5f ).
Discussion
It is has been clearly identified that the Ras pathway has a crucial role in human melanoma. However, only 15% of human melanomas contain a Ras gene mutation. The cases containing a constitutively activated Ras mutation are even less (Ball et al., 1994; van Elsas et al., 1995) . More frequent in melanoma are mutations in signaling elements downstream of Ras, such as B-Raf and phosphatase and tensin homolog (Pollock et al., 2003; Wu et al., 2003; Ikediobi et al., 2006) , but none of them is sufficient to initiate melanoma by itself (Sumimoto et al., 2004; Cully et al., 2006; Dankort et al., 2009 ). Changes in upstream signaling elements provide a complementary approach to influence the Ras pathway. As Ras activators, RasGRPs could be candidate molecules to have such a role.
Our data show substantial RasGRP3 expression in multiple human melanoma cell lines as well as in subset of human melanoma tissue samples. Our findings provide evidence that RasGRP3 expression has broader tissue distribution than has been generally recognized (Teixeira et al., 2003; Roberts et al., 2004; Coughlin et al., 2005) . The elevated RasGRP3 level does not appear to result from increased copy number of RasGRP3 in either melanoma tumors or melanoma cell lines (Bastian et al., 2003; Bauer and Bastian, 2006; Stark and Hayward, 2007) . On the other hand, RasGRP3 is subject both to developmental silencing as well as induction by growth factors (Roberts et al., 2004) .
Suppression of endogenous RasGRP3 inhibited cell proliferation and anchorage-independent growth and xenograft tumor growth of melanoma cell lines. Thus, the endogenous RasGRP3 contributes to the phenotype of multiple melanoma cell lines. This finding was strongly supported by the effects of overexpressing RasGRP3 in normal human adult melanocytes, which caused greatly enhanced cell growth and conferred tumorigenicity. Suppression of endogenous RasGRP3 expression in melanoma cell lines reduced Ras-GTP formation as well as c-Met expression and Akt phosphorylation downstream from HGF or EGF stimulation. We conclude that the regulation of wildtype Ras at its physiological expression level by upstream growth factors is mediated in part through endogenous RasGRP3 in human melanoma cells. Thus, RasGRP3/Ras represents an important node linking the HGF/c-Met and PI3K/Akt signaling pathways in melanoma. These findings help fill out our current understanding of the HGF/C-Met/Ras/PI3K/AKT signaling networks in melanoma (Takayama et al., 1997; Khwaja et al., 1997; Furge et al., 2001; Orian-Rousseau et al., 2007) . As described by other researchers, a BRAF mutation (V600E) is the most common mutation in human melanoma (Haluska and Ibrahim, 2006) . Compared with wild-type BRAF, BRAF V600E shows around 500-fold higher activity, causing sustained activation of ERK signaling (Hingorani et al., 2003; Houben et al., 2004; Ikenoue et al., 2003 Ikenoue et al., , 2004 Karasarides et al., 2004) . Seven out of the eight tested melanoma cell lines contain a BRAF mutation (V600E) (Supplementary Table 3 ). Highly activated extracellular signal-regulated kinase (ERK)1/2 was detected in all tested melanoma cell lines. Treatment of HGF and EGF did not lead to further activation of ERK1/2, except in the SK-MEL-5 cells. Inhibition of RasGRP3 affected neither the basal level of ERK1/2 activation nor HGF-induced ERK1/2 activation (data not show).
Rap1 is another member of the Ras family of small GTPases and a target of RasGRP3 (Yamashita et al., 2000) . Along with Ras, Rap1 has been shown to influence melanoma tumorigenesis and metastasis through regulating the activation of the mitogenactivated protein kinase pathway and integrin activation (Gao et al., 2006) . Its activity in human melanoma is regulated not only by activators but also by an inactivator, Rap1 GTPase-activating protein (GAP). Rap1GAP expression was decreased in human melanoma tumors and cell lines, but not in benign nevus cells, reflecting promoter hypermethylation (Zheng et al., 2009) . This downregulation of Rap1Gap caused marked elevation of Rap1 activation and promoted melanoma cell proliferation, survival and migration (Zheng et al., 2009) . In preliminary experiments, we did not observe a change in Rap1-GTP levels upon suppression of RasGRP3 expression in the SK-MEL-5 cells (data not shown). If correct, this may suggest that the rate limiting regulator of Rap1, at least in this cell line, is either RasGAP or one or more of the other known RapGEFs in addition to RasGRP3 (Guo et al., 2001; Ohba et al., 2001) .
Serrano and Chodosh reported that highly expressed constitutive H-Ras-induced senescence in human or rodent primary cells (Serrano et al., 1997; Sarkisian et al., 2007) . But Chodosh et al. also showed that a lower level of oncogenic RAS expression did not caused Expression and function of RasGRP3 in human melanoma D Yang et al cellular senescence. In contrast, it promoted continuous cell proliferation in vitro and tumor formation in vivo (Sarkisian et al., 2007) . In addition, endogenous expression of constitutive active K-RAS is sufficient to initiate epithelial cells transformation and promote tumorigenesis without detectable senescence (Tuveson et al., 2004) . These studies support the idea that oncogenic effects of Ras family members are critically dependent on the intensity of the Ras signal and the type of Ras isoform. In our study, introduction of RasGRP3 caused outgrowth of transformed human primary melanocytes. As an activator of multiple Ras isoforms, the downstream biological effects of overexpressed RasGRP3 should be more complex than biological response triggered by overexpression of a single Ras isoform. Compared with the uncontrolled constitutively active Ras, RasGRP3 introduced into melanocytes still performed as a normal cellular signal transducer, which was able to respond to extracellular stimulation. The intensity of the downstream Ras signal would thus depend on the intensity of biological extracellular stimulation rather than on the expression level of single mutated activated Ras. Additionally, the outgrowing RasGRP3 overexpressing cells will necessarily reflect selection against senescence, to the degree that it might have occurred in some cells.
In summary, our findings further highlight the importance of the RasGRP3/Ras pathway in melanoma, as already clear from analysis of mutations in B-Raf and phosphatase and tensin homolog associated with melanoma, but also emphasize the complexity of this pathway. As it was expressed at a high level in a subset of human melanomas, contributing to melanoma tumorigenicity and involved in the phosphoinositide signaling pathway, RasGRP3 represents a novel potential therapeutic target for certain human melanomas.
Materials and methods

Cell lines, reagents and antibodies
The MALME-3M, M14, SK-MEL-5, SK-MEL-2, SK-MEL-28, LOX-IMVI, UACC-257 and UACC-62 cell lines were obtained from Jackson Laboratory (Bar Harbor, ME, USA). Complete medium for all these cell lines consisted of RPMI-1640 medium supplemented with 10% fetal bovine serum (ATCC, Manassas, VA, USA). The human epidermal melanocytes (adult) were purchased from Invitrogen and cultured in Medium 254 supplemented with PMA-Free Human Melanocyte Growth Supplement-2 (Invitrogen, Carlsbad, CA, USA). RasGRP3 rabbit monoclonal antibody was from Cell Signaling (Beverly, MA, USA), mouse anti-Ras monoclonal antibody was purchased from Upstate (Lake Placid, NY, USA). Primary antibodies for p-AKT1/2/3, AKT1/2/3, S100 and the anti-H-Ras polyclonal antibody were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse anti-V5 monoclonal antibody, the mouse anti-tyrosinase monoclonal antibody, the Virapower Lentiviral expression system, CyQuant NF cell proliferation assay kit, Lipofectamine 2000, blasticidin and precast Tris-glycine gels were from Invitrogen. Recombinant human HGF, vascular endothelial growth factor, EGF, transforming growth factor-b and tumor necrosis factor-a were from R&D Systems (Minneapolis, MN, USA).
In situ hybridization histochemistry Two published probes were generated and inserted into a Bluescript II SK vector (Stratagene, La Jolla, CA, USA) (Yamashita et al., 2000; Roberts et al., 2004) . Slides containing paraffin-embedded human multiple melanoma tissue arrays (US Biomax Inc., Rockville, MD, USA) were labeled with the two probes. For detailed experimental procedures, see Supplementary Materials and methods.
Generation of tetracycline-inducible H1 lentiviral shRNA constructs The sequences encoding the shRNAs for this study are listed in Supplementary Table 2 . The pLenti4/BLOCK-iT-DEST vectors containing specific shRNA were constructed according to the manufacturer's instructions. All the constructs were verified by DNA sequencing. The lentiviral constructs were then produced and titered.
Establishment of tetracycline-regulated shRNA expressing stable cell lines and the cell lines stably overexpressing wild-type RasGRP3 or its shRNA854 resistant mutant TetR-expressing host cell lines derived from M14 and SK-MEL-5 cells were generated following the manufacturer's instructions. These two cell lines are heterogeneous populations of blasticidin-resistant cells stably expressing the Tet repressor. Subsequently the TetR-expressing host cell lines were infected with the lentiviral vectors as indicated and subjected to Zeocin (500 mg/ml) and blasticidin (10 mg/ml) selection for 3 weeks. Studies were carried out on the pooled, antibiotic-resistant cells.
Cell proliferation assay
Cell proliferation was measured using the CyQuant NF cell proliferation assay or using the IncuCyte instrument (Essen Instruments Inc., Ann Harbor, MI, USA) as described in detail in the Supplementary Information.
Analysis of Ras activation using the Raf1-RBD-GST pull-down assay Activation of Ras was evaluated as described by Teixeira et al. (2003) .
Western blot assay
The samples containing 40 mg total protein were separated by electrophoresis and transferred onto Immobilon-P membranes (Millipore Corporation, Bedford, MA, USA). After the membranes were blocked and labeled with the appropriate primary and secondary antibodies, the signal was developed by ECL (Amersham, Piscataway, NJ, USA) and imaged on BioMax XAR or MR films (Kodak, Rochester, NJ, USA).
Growth of cell lines in mouse xenograft system
Mouse studies were performed under a protocol approved by the National Cancer Institute and NIH Animal Care and Use Committee. NOD.SCID/NCr male mice (NIH, Frederick, MD, USA) were injected subcutaneously in the flanks with 5 Â 10 6 or 1 Â 10 7 cells per injection. In the case of those cell lines containing tetracycline-inducible expression systems, on the eighth day after injection half the animals in each treatment group were shifted to food containing deoxytetracy- cline. The animals were killed after 8 weeks for mice injected with the SK-MEL-5 derived cell lines, RasGRP3-melanocytes or the control melanocytes, and after 12 weeks for mice injected with the M14 derived cell lines.
Anchorage-independent growth assay in soft agar Cells were plated and cultured for 10 days as described in details in Supplementary Information. Phase contrast images were taken and the number of colonies greater than the median size of the non-treated controls was determined using Image J software (developed at the US National Institutes of Health and available on the Internet at http://rsb.info.nih.gov/nih-image/).
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